Related Experiment Video
Updated: Jul 10, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Genetics and Screening in Prostate Cancer
Joseph G R Partuzo1, Belén Mora-Garijo2, Jonathan Hwang1
1Department of Urology, Georgetown University School of Medicine, Washington, DC, USA.
None:
Prostate cancer is a highly prevalent and heritable malignancy with marked disparities in incidence, stage at diagnosis, and mortality among minority populations. While localized disease carries an excellent prognosis, outcomes decline sharply in advanced and metastatic cases, underscoring the need for improved risk stratification. This article reviews the role of germline and somatic genetic alterations in prostate cancer development, prognosis, and treatment selection. It outlines current guideline-based indications for genetic testing, emerging evidence supporting broader testing strategies, and evolving tools including polygenic risk scores, tumor-derived genomic classifiers, digital histopathology platforms, and circulating tumor DNA.
Related Concept Videos
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
